Indrayani Biotech Limited
BLOCK NO 1 MODULE NO 32, 33
SIDCO ELECTRONICS COMPLEX
THIRU VI KA INDUSTRIAL ESTATE
GUINDY CHENNAI 600 032

CIN: L40100TN1992PLC129301

22.06.2021

To,
Dept. of Corporate Services
Bombay Stock Exchange Limited
Floor 25, P J Tower, Dalal Street,
Mumbai 400001

(Scrip code: 526445)

Dear Sir/Madam

Sub: Covering letter with the Board outcome for the Board meeting held on 22nd June, 2021

Please find attached the board outcome for the meeting held on i.e. 22.06.2021

Kindly take the same on your record

Thanking you

Yours Sincerely,

INDRAYANI BIOTECH LTD

KASIRAMAN SAYEE SUNDAR
Managing Director
Din: 01295584

Indrayani Biotech Limited
BLOCK NO 1 MODULE NO 32, 33
SIDCO ELECTRONICS COMPLEX
THIRU VI KA INDUSTRIAL ESTATE
GUINDY CHENNAI 600 032

CIN: L40100TN1992PLC129301

Date: 22.06.2021

To,
Dept. of Corporate Services
BSE Limited
P J Tower, Dalal Street,
Mumbai – 400001

(Scrip code: 526445)

Ref: Regulation 30 and Regulation 33 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Sub: Outcome of the Board meeting

Dear Sir/Madam,

This is to inform you that the meeting of the Board of Directors of the company has; at its meeting held on 22nd June 2021 i.e. (today) considered and approved the following:

1. The audited merged financial results for the Quarter ended 30th June,30thSeptember ,31stDecember ,31stMarch of the years 2018-19 and 2019-20 respectively and also for the Quarter ended 30th June of 2020-2021

2. Appointment of Mr.R.Dhinakaran as Chief Coordination Officer of the Company with effect from 21st May 2021.His brief profile has been attached below as annexure.

   The Board also hereby informsthat Indrayani Biotech Limited has been selected in the final list of Eligible Resolution Applicants in the matter of Spring Field Shelters Private Limited, Coimbatore which is under CIRP. The Company would be submitting a Resolution Plan on or before 6th July 2021 .This is for your information, upon successful approval, the same would be intimated to the members.

The meeting commenced at 4.00 pm and concluded at 7.45 pm.

Indrayani Biotech Limited
BLOCK NO 1 MODULE NO 32, 33
SIDCO ELECTRONICS COMPLEX
THIRU VI KA INDUSTRIAL ESTATE
GUINDY CHENNAI 600 032

Kindly request you to take the same on your record.

Thanking you

Yours Sincerely,

KASIRAMAN SAYEE SUNDAR
Managing Director
DIN: 01295584

INDRAYANI BIOTECH LTD

Indrayani Biotech Limited
BLOCK NO 1 MODULE NO 32, 33
SIDCO ELECTRONICS COMPLEX
THIRU VI KA INDUSTRIAL ESTATE
GUINDY CHENNAI 600 032

Annexure

Brief profile of Mr. DhinakaranRajagopal

Dhinakaran Rajagopal has 30 years of Industry experience. He comes with a rich experience of IT services and Management. He had been with Infosys Ltd for the past 20 years holding several management positions serving international banking and financial services clients.Prior to that, he has served top public sector companies in India like Indian Oil Corporation Limited and Bharat Heavy Electricals Limited.He has won several awards at organisation level and national level during his professional life. He has won the National Young IT Professional award by Computer Society of India during 1999.He had won several awards including the organisation level Excellence award for best account management within Infosys.He is an Electrical and Electronics Engineer by qualification and a University rank holder

INDRAYANI BIOTECH LIMITED

Regd. Office :SIDCO Electronics Complex, #32 33 Block: I 3rd Floor Thiru Vi Ka Industrial Estate SIDCO Industrial Estate Guindy Chennai Tamil Nadu 600032.

AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE 2018

Rs. In Lakhs

	PARTICULARS				
Sr No	**PARTICULARS**	**3 months ended 30/06/2018**	**3 months ended 31/03/2017**	**3 months ended 30/06/2017**	**Previous Year ended 31/03/2017**
A	Date of start of reporting period	04-01-2018	01-01-2018	04-01-2018	04-01-2017
B	Date of end of reporting period	30/6/2018	31-03-2018	30/6/2018	31/3/2018
C	Whether results are audited or unaudited	Audited	Audited	Audited	Audited
D	Nature of report standalone or consolidated	Standalone	Standalone	Standalone	Standalone
1	**Income from Operations**				
	(a) Net Sales/Revenue from Operations	808.87		-	
	(b) Other Income	9.31	-	-	-
	Total Income from Operations	**818.18**	-	-	-
				-	
2	**Expenses**			-	
	(a) Cost of Materials consumed	542.25		-	
	(b) Purchase of stock-in-trade	-		-	
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-		-	
	(d) Employee benefits expenses	235.53	1.20	0.60	2.70
	(e) Finance Costs	29.72	0.03	-	0.03
	(f) Depreciation and amortisation expense	20.64	-	-	-
	(g) Other expenses	64.67	3.04	3.76	7.66
	Total Expenses	**892.81**	**4.27**	**4.36**	**10.39**
3	**Total profit / (Loss) before exceptional items and tax**	**(74.63)**	**(4.27)**	**(4.36)**	**(10.39)**
4	Exceptional Items			-	
5	**Total profit / (Loss) before tax**	(74.63)	(4.27)	(4.36)	(10.39)
7	**Tax Expenses**				
8	Current Tax				
9	Deferred Tax				
10	**Total Tax Expenses**	-	-	-	-

11	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement				
14	**Net Profit Loss for the period from continuing operations**	(74.63)	(4.27)	(4.36)	(10.39)
15	**Profit (loss) from discontinued operations before tax**			-	
16	**Tax expense of discontinued operations**			-	
17	**Net profit (loss) from discontinued operation after tax**			-	
19	**Share of profit (loss) of associates and joint ventures accounted for using equity method**			-	
21	**Total profit (loss) for period**	(74.63)	(4.27)	(4.36)	(10.39)
22	**Other comprehensive income net of taxes**			-	
23	**Total Comprehensive Income for the period**			-	
24	**Total profit or loss, attributable to**			-	
	Profit or loss, attributable to owners of parent	(74.63)	(4.27)	(4.36)	(10.39)
	Total profit or loss, attributable to non-controlling interests			-	
25	**Total Comprehensive income for the period attributable to**			-	
	Comprehensive income for the period attributable to owners of parent			-	
	Total comprehensive income for the period attributable to owners of parent noncontrolling interests			-	
26	**Details of equity share capital**			-	
	Paid-up equity share capital	3,422.72	364.39	364.39	364.39
	Face value of equity share capital	10.00	10.00	10.00	10.00
27	**Details of debt securities**				
	Paid-up debt capital				
	Face value of debt securities				
28	**Reserves excluding revaluation reserve**				
29	**Debenture redemption reserve**				
30	**Earnings per share**				
i	**Earnings per equity share for continuing operations**	(0.22)	(0.12)	(0.12)	(0.29)
	Basic earnings (loss) per share from continuing operations	(0.22)	(0.12)	(0.12)	(0.29)
	Diluted earnings (loss) per share from continuing operations				
ii	**Earnings per equity share for discontinued operations**				
	Basic earnings (loss) per share from discontinued operations				
	Diluted earnings (loss) per share from discontinued operations				
iii	**Earnings per equity share**				
	Basic earnings (loss) per share from continuing and discontinued operations	(0.22)	(0.12)	(0.12)	(0.29)
	Diluted earnings (loss) per share from continuing and discontinued operations	(0.22)	(0.12)	(0.12)	(0.29)
31	**Debt equity ratio**				
32	**Debt service coverage ratio**				
33	**Interest service coverage ratio**				
34	**Disclosure of notes on financial results**				

Notes:

1. The audited merged financial results for the Quarter ended June 30th,September 30th ,December 31st ,March 31st of 2018-19 and 2019-20 and for the Quarter ended 30th June of 2020-2021 being forwarded to the Bombay stock exchange and is also available in the website of the Company (www.indrayani.com)

2. The above financial results have been filed pursuant to the merger order by the Hon'ble National Company Law Tribunal Chennai dated 05.08.2020

3. The Company operates in single business segment. Hence no segment wise reporting figures are published.

4. There were no investor complaints pending at the beginning or at the end of the quarter. No complaints were received during the quarter

5. Previous period figures have been regrouped wherever necessary.

INDRAYANI BIOTECH LTD

Place: Chennai

Date: 22.06.2021

K SAYEE SUNDAR

MANAGING DIRECTOR

DIN: 01295584

INDRAYANI BIOTECH LIMITED

Regd. Office :SIDCO Electronics Complex, #32 33 Block: I 3rd Floor Thiru Vi Ka Industrial Estate SIDCO Industrial Estate Guindy Chennai Tamil Nadu 600032.

AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th Sep 2018

Rs. In Lakhs

Sr No	PARTICULARS	3 months ended 30/09/2018	3 months ended 30/09/2017	Year to date figures for current period ended 30/09/2018	Previous Year ended 31/03/2017
A	Date of start of reporting period	01-07-2018	01-07-2017	04-01-2018	04-01-2017
B	Date of end of reporting period	30-09-2018	30-09-2017	30-09-2018	31-03-2018
C	Whether results are audited or unaudited	Audited	Audited	Audited	Audited
D	Nature of report standalone or consolidated	Standalone	Standalone	Standalone	Standalone
1	**Income from Operations**				
	(a) Net Sales/Revenue from Operations	1,113.62		1,922.49	
	(b) Other Income	8.17	-	17.48	-
	Total Income from Operations	**1,121.79**	-	**1,939.97**	-
				-	
2	**Expenses**			-	
	(a) Cost of Materials consumed	776.88		1,319.13	
	(b) Purchase of stock-in-trade	-		-	
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-		-	
	(d) Employee benefits expenses	315.90	0.90	551.44	2.70
	(e) Finance Costs	26.25	0.02	55.97	0.03
	(f) Depreciation and amortisation expense	22.81	-	43.45	-
	(g) Other expenses	90.52	1.31		7.66
	Total Expenses	**1,232.36**	**2.23**	**2,125.16**	**10.39**
3	**Total profit / (Loss) before exceptional items and tax**	**(110.57)**	**(2.23)**	**(185.20)**	**(10.39)**
4	Exceptional Items			-	
5	**Total profit / (Loss) before tax**	(110.57)	(2.23)	(185.20)	(10.39)
7	**Tax Expenses**				
8	Current Tax				
9	Deferred Tax				
10	**Total Tax Expenses**	-	-	-	-

11	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement				
14	**Net Profit Loss for the period from continuing operations**	(110.57)	(2.23)	(185.20)	(10.39)
15	**Profit (loss) from discontinued operations before tax**			-	
16	**Tax expense of discontinued operations**			-	
17	**Net profit (loss) from discontinued operation after tax**			-	
19	**Share of profit (loss) of associates and joint ventures accounted for using equity method**			-	
21	**Total profit (loss) for period**	(110.57)	(2.23)	(185.20)	(10.39)
22	**Other comprehensive income net of taxes**			-	
23	**Total Comprehensive Income for the period**			-	
24	**Total profit or loss, attributable to**			-	
	Profit or loss, attributable to owners of parent	(110.57)	(2.23)	(185.20)	(10.39)
	Total profit or loss, attributable to non-controlling interests			-	
25	**Total Comprehensive income for the period attributable to**			-	
	Comprehensive income for the period attributable to owners of parent			-	
	Total comprehensive income for the period attributable to owners of parent noncontrolling interests			-	
26	**Details of equity share capital**			-	
	Paid-up equity share capital	-	-	-	-
	Face value of equity share capital	-	-	-	-
27	**Details of debt securities**				
	Paid-up debt capital	3,422.72	364.39	3,422.72	364.39
	Face value of debt securities	10.00	10.00	10.00	10.00
28	**Reserves excluding revaluation reserve**				
29	**Debenture redemption reserve**				
30	**Earnings per share**				
i	**Earnings per equity share for continuing operations**	(0.32)	(0.06)	(0.54)	(0.29)
	Basic earnings (loss) per share from continuing operations	(0.32)	(0.06)	(0.54)	(0.29)
	Diluted earnings (loss) per share from continuing operations				
ii	**Earnings per equity share for discontinued operations**				
	Basic earnings (loss) per share from discontinued operations				
	Diluted earnings (loss) per share from discontinued operations				
iii	**Earnings per equity share**				
	Basic earnings (loss) per share from continuing and discontinued operations	(0.32)	(0.06)	(0.54)	(0.29)
	Diluted earnings (loss) per share from continuing and discontinued operations	(0.32)	(0.06)	(0.54)	(0.29)
31	**Debt equity ratio**				
32	**Debt service coverage ratio**				
33	**Interest service coverage ratio**				
34	**Disclosure of notes on financial results**				

Notes:

1. The audited merged financial results for the Quarter ended June 30th,September 30th ,December 31st ,March 31st of 2018-19 and 2019-20 and for the Quarter ended 30th June of 2020-2021 being forwarded to the Bombay stock exchange and is also available in the website of the Company (www.indrayani.com)

2. The above financial results have been filed pursuant to the merger order by the Hon'ble National Company Law Tribunal Chennai dated 05.08.2020

3. The Company operates in single business segment. Hence no segment wise reporting figures are published.

4. There were no investor complaints pending at the beginning or at the end of the quarter. No complaints were received during the quarter

5. Previous period figures have been regrouped wherever necessary.

INDRAYANI BIOTECH LTD

Place: Chennai

Date: 22.06.2021

K SAYEE SUNDAR

MANAGING DIRECTOR

DIN: 01295584

INDRAYANI BIOTECH LIMITED

Regd. Office :SIDCO Electronics Complex, #32 33 Block: I 3rd Floor Thiru Vi Ka Industrial Estate SIDCO Industrial Estate Guindy Chennai Tamil Nadu 600032.

AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31st DECEMBER 2018

Rs. In Lakhs

	PARTICULARS				
Sr No	**PARTICULARS**	**3 months ended 31/12/2018**	**3 months ended 30/09/2017**	**Year to date figures for current period ended 30/09/2018**	**Previous Year ended 31/03/2017**
A	Date of start of reporting period	01-10-2018	01-10-2017	01-04-2018	01-04-2017
B	Date of end of reporting period	31-12-2018	31-12-2017	31-03-2018	31-03-2017
C	Whether results are audited or unaudited	Audited	Audited	Audited	Audited
D	Nature of report standalone or consolidated	Standalone	Standalone	Standalone	Standalone
1	**Income from Operations**				
	(a) Net Sales/Revenue from Operations	1,320.04		3,242.53	
	(b) Other Income	6.31	-	23.80	-
	Total Income from Operations	**1,326.35**	**-**	**3,266.32**	**-**
				-	
2	**Expenses**			-	
	(a) Cost of Materials consumed	725.58		2,044.71	
	(b) Purchase of stock-in-trade	-		-	
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-		-	
	(d) Employee benefits expenses	301.18	0.90	852.61	2.70
	(e) Finance Costs	26.66		82.63	0.03
	(f) Depreciation and amortisation expense	31.50		74.95	-
	(g) Other expenses	91.32	0.66		7.66
	Total Expenses	**1,176.24**	**1.56**	**3,054.90**	**10.39**
3	**Total profit / (Loss) before exceptional items and tax**	**150.11**	**(1.56)**	**211.43**	**(10.39)**
4	Exceptional Items			-	
5	**Total profit / (Loss) before tax**	150.11	(1.56)	211.43	(10.39)
7	**Tax Expenses**				
8	Current Tax	13.81			
9	Prior Period Tax	7.63			
10	**Total Tax Expenses**	**21.43**	-	-	-

11	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement				
14	**Net Profit Loss for the period from continuing operations**	128.68	(1.56)	211.43	(10.39)
15	**Profit (loss) from discontinued operations before tax**			-	
16	**Tax expense of discontinued operations**			-	
17	**Net profit (loss) from discontinued operation after tax**			-	
19	**Share of profit (loss) of associates and joint ventures accounted for using equity method**			-	
21	**Total profit (loss) for period**	128.68	(1.56)	211.43	(10.39)
22	**Other comprehensive income net of taxes**			-	
23	**Total Comprehensive Income for the period**			-	
24	**Total profit or loss, attributable to**			-	
	Profit or loss, attributable to owners of parent	128.68	(1.56)	211.43	(10.39)
	Total profit or loss, attributable to non-controlling interests			-	
25	**Total Comprehensive income for the period attributable to**			-	
	Comprehensive income for the period attributable to owners of parent			-	
	Total comprehensive income for the period attributable to owners of parent noncontrolling interests			-	
26	**Details of equity share capital**			-	
	Paid-up equity share capital	3,422.72	364.39	3,422.72	364.39
	Face value of equity share capital	10.00	10.00	10.00	10.00
27	**Details of debt securities**				
	Paid-up debt capital				
	Face value of debt securities				
28	**Reserves excluding revaluation reserve**				
29	**Debenture redemption reserve**				
30	**Earnings per share**				
i	**Earnings per equity share for continuing operations**	0.38	(0.04)	0.62	(0.29)
	Basic earnings (loss) per share from continuing operations	0.38	(0.04)	0.62	(0.29)
	Diluted earnings (loss) per share from continuing operations				
ii	**Earnings per equity share for discontinued operations**				
	Basic earnings (loss) per share from discontinued operations				
	Diluted earnings (loss) per share from discontinued operations				
iii	**Earnings per equity share**				
	Basic earnings (loss) per share from continuing and discontinued operations	0.38	(0.04)	0.62	(0.29)
	Diluted earnings (loss) per share from continuing and discontinued operations	0.38	(0.04)	0.62	(0.29)
31	**Debt equity ratio**				
32	**Debt service coverage ratio**				
33	**Interest service coverage ratio**				
34	**Disclosure of notes on financial results**				

Notes:

1. The audited merged financial results for the Quarter ended June 30th,September 30th ,December 31st ,March 31st of 2018-19 and 2019-20 and for the Quarter ended 30th June of 2020-2021 being forwarded to the Bombay stock exchange and is also available in the website of the Company (www.indrayani.com)

2. The above financial results have been filed pursuant to the merger order by the Hon'ble National Company Law Tribunal Chennai dated 05.08.2020

3. The Company operates in single business segment. Hence no segment wise reporting figures are published.

4. There were no investor complaints pending at the beginning or at the end of the quarter. No complaints were received during the quarter

5. Previous period figures have been regrouped wherever necessary.

INDRAYANI BIOTECH LTD

Place: Chennai

Date: 22.06.2021

K SAYEE SUNDAR

MANAGING DIRECTOR

DIN: 01295584

INDRAYANI BIOTECH LIMITED

Regd. Office :SIDCO Electronics Complex, #32 33 Block: I 3rd Floor Thiru Vi Ka Industrial Estate SIDCO Industrial Estate Guindy Chennai Tamil Nadu 600032.

AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31st March 2019

Rs. In Lakhs

	PARTICULARS				
Sr No	**PARTICULARS**	**3 months ended 31/03/2019**	**3 months ended 31/03/2018**	**Year to date figures for current period ended 31/12/2019**	**Previous Year ended 31/03/2017**
A	Date of start of reporting period	01-01-2019	01-01-2018	01-04-2018	01-04-2017
B	Date of end of reporting period	31-03-2019	31-03-2018	31-03-2019	31-03-2018
C	Whether results are audited or unaudited	Audited	Audited	Audited	Audited
D	Nature of report standalone or consolidated	Standalone	Standalone	Standalone	Standalone
1	**Income from Operations**				
	(a) Net Sales/Revenue from Operations	1,455.29		4,697.81	
	(b) Other Income	21.24	-	45.04	-
	Total Income from Operations	**1,476.53**	**-**	**4,742.85**	**-**
				-	
2	**Expenses**			-	
	(a) Cost of Materials consumed	951.24		2,995.94	
	(b) Purchase of stock-in-trade	-		-	
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-		-	
	(d) Employee benefits expenses	320.32	1.20	1,172.93	2.70
	(e) Finance Costs	28.95	0.03	111.57	0.03
	(f) Depreciation and amortisation expense	33.67	-	108.62	-
	(g) Other expenses	70.93	3.04	317.44	7.66
	Total Expenses	**1,405.11**	**4.27**	**4,706.51**	**10.39**
3	**Total profit / (Loss) before exceptional items and tax**	**71.42**	**(4.27)**	**36.34**	**(10.39)**
4	Exceptional Items			-	
5	**Total profit / (Loss) before tax**	71.42	(4.27)	36.34	(10.39)
7	**Tax Expenses**				
8	Current Tax				
9	Deferred Tax				
10	**Total Tax Expenses**	-	-	-	-

11	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement				
14	**Net Profit Loss for the period from continuing operations**	71.42	(4.27)	36.34	(10.39)
15	**Profit (loss) from discontinued operations before tax**			-	
16	**Tax expense of discontinued operations**			-	
17	**Net profit (loss) from discontinued operation after tax**			-	
19	**Share of profit (loss) of associates and joint ventures accounted for using equity method**			-	
21	**Total profit (loss) for period**	71.42	(4.27)	36.34	(10.39)
22	**Other comprehensive income net of taxes**			-	
23	**Total Comprehensive Income for the period**			-	
24	**Total profit or loss, attributable to**			-	
	Profit or loss, attributable to owners of parent	71.42	(4.27)	36.34	(10.39)
	Total profit or loss, attributable to non-controlling interests			-	
25	**Total Comprehensive income for the period attributable to**			-	
	Comprehensive income for the period attributable to owners of parent			-	
	Total comprehensive income for the period attributable to owners of parent noncontrolling interests			-	
26	**Details of equity share capital**			-	
	Paid-up equity share capital	3,422.72	364.39	3,422.72	364.39
	Face value of equity share capital	10.00	10.00	10.00	10.00
27	**Details of debt securities**				
	Paid-up debt capital				
	Face value of debt securities				
28	**Reserves excluding revaluation reserve**				
29	**Debenture redemption reserve**				
30	**Earnings per share**				
i	**Earnings per equity share for continuing operations**	0.21	(0.12)	0.11	(0.29)
	Basic earnings (loss) per share from continuing operations	0.21	(0.12)	0.11	(0.29)
	Diluted earnings (loss) per share from continuing operations				
ii	**Earnings per equity share for discontinued operations**				
	Basic earnings (loss) per share from discontinued operations				
	Diluted earnings (loss) per share from discontinued operations				
iii	**Earnings per equity share**				
	Basic earnings (loss) per share from continuing and discontinued operations	0.21	(0.12)	0.11	(0.29)
	Diluted earnings (loss) per share from continuing and discontinued operations	0.21	(0.12)	0.11	(0.29)
31	**Debt equity ratio**				
32	**Debt service coverage ratio**				
33	**Interest service coverage ratio**				
34	**Disclosure of notes on financial results**				

Notes:

1. The audited merged financial results for the Quarter ended June 30th,September 30th ,December 31st ,March 31st of 2018-19 and 2019-20 and for the Quarter ended 30th June of 2020-2021 being forwarded to the Bombay stock exchange and is also available in the website of the Company (www.indrayani.com)

2. The above financial results have been filed pursuant to the merger order by the Hon'ble National Company Law Tribunal Chennai dated 05.08.2020

3. The Company operates in single business segment. Hence no segment wise reporting figures are published.

4. There were no investor complaints pending at the beginning or at the end of the quarter. No complaints were received during the quarter

5. Previous period figures have been regrouped wherever necessary.

INDRAYANI BIOTECH LTD

Place: Chennai

Date: 22.06.2021

K SAYEE SUNDAR

MANAGING DIRECTOR

DIN: 01295584

INDRAYANI BIOTECH LIMITED

Regd. Office :SIDCO Electronics Complex, #32 33 Block: I 3rd Floor Thiru Vi Ka Industrial Estate SIDCO Industrial Estate Guindy Chennai Tamil Nadu 600032.

AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th June 2019

Rs. In Lakhs

Sr No	PARTICULARS	3 months ended 30/06/2019	3 months ended 31/03/2019	3 months ended 30/06/2018	Previous Year ended 31/03/2019
	PARTICULARS				
A	Date of start of reporting period	01-04-2019	01-01-2019	01-04-2018	01-04-2018
B	Date of end of reporting period	30-06-2019	31-03-2019	30-06-2018	31-03-2019
C	Whether results are audited or unaudited	Audited	Audited	Audited	Audited
D	Nature of report standalone or consolidated	Standalone	Standalone	Standalone	Standalone
1	**Income from Operations**				
	(a) Net Sales/Revenue from Operations	1,013.55	1,455.29	808.87	**4,697.81**
	(b) Other Income	2.98	21.24	9.31	45.04
	Total Income from Operations	**1,016.53**	**1,476.53**	**818.18**	**4,742.85**
				-	
2	**Expenses**			-	
	(a) Cost of Materials consumed	712.63	951.24	542.25	2,995.94
	(b) Purchase of stock-in-trade	-			
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-		-	
	(d) Employee benefits expenses	307.94	320.32	235.53	1,172.93
	(e) Finance Costs	27.82	28.95	29.72	111.57
	(f) Depreciation and amortisation expense	19.27	33.67	20.64	108.62
	(g) Other expenses	79.70	70.93	64.67	317.44
	Total Expenses	**1,147.37**	**1,405.11**	**892.81**	**4,706.51**
3	**Total profit / (Loss) before exceptional items and tax**	**(130.84)**	**71.42**	**(74.63)**	**36.34**
4	Exceptional Items			-	
5	**Total profit / (Loss) before tax**	(130.84)	71.42	(74.63)	36.34
7	**Tax Expenses**				
8	Current Tax				20.34
9	Deferred Tax				11.24
10	**Total Tax Expenses**	-	-	-	**31.58**
11	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement				
14	**Net Profit Loss for the period from continuing operations**	(130.84)	71.42	(74.63)	4.76
15	**Profit (loss) from discontinued operations before tax**			-	
16	**Tax expense of discontinued operations**			-	
17	**Net profit (loss) from discontinued operation after tax**			-	
19	**Share of profit (loss) of associates and joint ventures accounted for using equity method**			-	
21	**Total profit (loss) for period**	(130.84)	71.42	(74.63)	4.76
22	**Other comprehensive income net of taxes**			-	
23	**Total Comprehensive Income for the period**			-	
24	**Total profit or loss, attributable to**			-	
	Profit or loss, attributable to owners of parent	(130.84)	71.42	(74.63)	4.76
	Total profit or loss, attributable to non-controlling interests			-	
25	**Total Comprehensive income for the period attributable to**			-	
	Comprehensive income for the period attributable to owners of parent			-	

	Total comprehensive income for the period attributable to owners of parent noncontrolling interests			-	
26	**Details of equity share capital**			-	
	Paid-up equity share capital	3,422.72	364.39	3,422.72	364.39
	Face value of equity share capital	10.00	10.00	**10.00**	10.00
27	**Details of debt securities**				
	Paid-up debt capital				
	Face value of debt securities				
28	**Reserves excluding revaluation reserve**				
29	**Debenture redemption reserve**				
30	**Earnings per share**				
i	**Earnings per equity share for continuing operations**	0.08	**0.18**	**(0.22)**	**0.01**
	Basic earnings (loss) per share from continuing operations	0.08	**0.18**	**(0.22)**	**0.01**
	Diluted earnings (loss) per share from continuing operations				
ii	**Earnings per equity share for discontinued operations**				
	Basic earnings (loss) per share from discontinued operations				
	Diluted earnings (loss) per share from discontinued operations				
iii	**Earnings per equity share**				
	Basic earnings (loss) per share from continuing and discontinued operations	0.08	0.18	(0.22)	0.01
	Diluted earnings (loss) per share from continuing and discontinued operations	0.08	0.18	(0.22)	0.01
31	**Debt equity ratio**				
32	**Debt service coverage ratio**				
33	**Interest service coverage ratio**				
34	**Disclosure of notes on financial results**				

Notes:

1. The audited merged financial results for the Quarter ended June 30th,September 30th ,December 31st ,March 31st of 2018-19 and 2019-20 and for the Quarter ended 30th June of 2020-2021 being forwarded to the Bombay stock exchange and is also available in the website of the Company (www.indrayani.com)

2. The above financial results have been filed pursuant to the merger order by the Hon'ble National Company Law Tribunal Chennai dated 05.08.2020

3. The Company operates in single business segment. Hence no segment wise reporting figures are published.

4. There were no investor complaints pending at the beginning or at the end of the quarter. No complaints were received during the quarter

5. Previous period figures have been regrouped wherever necessary.

INDRAYANI BIOTECH LTD

Place: Chennai

Date: 22.06.2021

K SAYEE SUNDAR

MANAGING DIRECTOR

DIN: 01295584

INDRAYANI BIOTECH LIMITED

Regd. Office :SIDCO Electronics Complex, #32 33 Block: I 3rd Floor Thiru Vi Ka Industrial Estate SIDCO Industrial Estate Guindy Chennai Tamil Nadu 600032.

AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th Sep 2019

Rs. In Lakhs

Sr No	PARTICULARS	3 months ended 30/09/2019	3 months ended 30/09/2018	6 months ended 30/09/2019	Previous Year ended 31/03/2019
A	Date of start of reporting period	01-07-2019	01-07-2018	01-04-2019	01-04-2018
B	Date of end of reporting period	30-09-2019	30-09-2018	30-09-2019	31-03-2019
C	Whether results are audited or unaudited	Audited	Audited	Audited	Audited
D	Nature of report standalone or consolidated	Standalone	Standalone	Standalone	Standalone
1	**Income from Operations**				
	(a) Net Sales/Revenue from Operations	1,201.33	1,113.62	2,214.88	**4,697.81**
	(b) Other Income	6.04	8.17	9.02	45.04
	Total Income from Operations	**1,207.38**	**1,121.79**	**2,223.90**	**4,742.85**
				-	
2	**Expenses**				
	(a) Cost of Materials consumed	726.83	776.88	1,439.47	2,995.94
	(b) Purchase of stock-in-trade	-			
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-		-	
	(d) Employee benefits expenses	276.49	315.90	584.43	1,172.93
	(e) Finance Costs	27.63	26.25	55.45	111.57
	(f) Depreciation and amortisation expense	21.30	22.81	40.58	108.62
	(g) Other expenses	69.28	90.52	148.98	317.44
	Total Expenses	**1,121.53**	**1,232.36**	**2,268.90**	**4,706.51**
3	**Total profit / (Loss) before exceptional items and tax**	**85.84**	**(110.57)**	**(45.00)**	**36.34**
4	Exceptional Items			-	
5	**Total profit / (Loss) before tax**	85.84	(110.57)	(45.00)	36.34
7	**Tax Expenses**				
8	Current Tax				20.34
9	Deferred Tax				11.24
10	**Total Tax Expenses**	-	-	-	**31.58**
11	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement				
14	**Net Profit Loss for the period from continuing operations**	85.84	(110.57)	(45.00)	4.76
15	**Profit (loss) from discontinued operations before tax**			-	
16	**Tax expense of discontinued operations**			-	
17	**Net profit (loss) from discontinued operation after tax**			-	
19	**Share of profit (loss) of associates and joint ventures accounted for using equity method**			-	
21	**Total profit (loss) for period**	85.84	(110.57)	(45.00)	4.76
22	**Other comprehensive income net of taxes**			-	
23	**Total Comprehensive Income for the period**			-	
24	**Total profit or loss, attributable to**			-	
	Profit or loss, attributable to owners of parent	85.84	(110.57)	(45.00)	4.76
	Total profit or loss, attributable to non-controlling interests			-	
25	**Total Comprehensive income for the period attributable to**			-	

	Comprehensive income for the period attributable to owners of parent			-	
	Total comprehensive income for the period attributable to owners of parent noncontrolling interests			-	
26	**Details of equity share capital**			-	
	Paid-up equity share capital	3,422.72	3,422.72	3,422.72	3,422.72
	Face value of equity share capital	10.00	10.00	10.00	10.00
27	**Details of debt securities**				
	Paid-up debt capital				
	Face value of debt securities				
28	**Reserves excluding revaluation reserve**				
29	**Debenture redemption reserve**				
30	**Earnings per share**				
i	**Earnings per equity share for continuing operations**	0.25	(0.32)	(0.13)	0.01
	Basic earnings (loss) per share from continuing operations	0.25	**(0.32)**	**(0.13)**	**0.01**
	Diluted earnings (loss) per share from continuing operations				
ii	**Earnings per equity share for discontinued operations**				
	Basic earnings (loss) per share from discontinued operations				
	Diluted earnings (loss) per share from discontinued operations				
iii	**Earnings per equity share**				
	Basic earnings (loss) per share from continuing and discontinued operations	0.25	(0.32)	(0.13)	0.01
	Diluted earnings (loss) per share from continuing and discontinued operations	0.25	(0.32)	(0.13)	0.01
31	**Debt equity ratio**				
32	**Debt service coverage ratio**				
33	**Interest service coverage ratio**				
34	**Disclosure of notes on financial results**				

Notes:

1. The audited merged financial results for the Quarter ended June 30th,September 30th ,December 31st ,March 31st of 2018-19 and 2019-20 and for the Quarter ended 30th June of 2020-2021 being forwarded to the Bombay stock exchange and is also available in the website of the Company (www.indrayani.com)

2. The above financial results have been filed pursuant to the merger order by the Hon'ble National Company Law Tribunal Chennai dated 05.08.2020

3. The Company operates in single business segment. Hence no segment wise reporting figures are published.

4. There were no investor complaints pending at the beginning or at the end of the quarter. No complaints were received during the quarter

5. Previous period figures have been regrouped wherever necessary.

INDRAYANI BIOTECH LTD

Place: Chennai

Date: 22.06.2021

K SAYEE SUNDAR

MANAGING DIRECTOR

DIN: 01295584

INDRAYANI BIOTECH LIMITED

Regd. Office :SIDCO Electronics Complex, #32 33 Block: I 3rd Floor Thiru Vi Ka Industrial Estate SIDCO Industrial Estate Guindy Chennai Tamil Nadu 600032.

AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31st Dec 2019

Rs. In Lakhs

Sr No	PARTICULARS	3 months ended 31/12/2019	3 months ended 31/12/2018	9 months ended 31/12/2019	Previous Year ended 31/03/2019
	PARTICULARS				
A	Date of start of reporting period	01-10-2019	01-10-2018	01-04-2019	01-04-2018
B	Date of end of reporting period	31-12-2019	31-12-2018	31-12-2019	31-03-2019
C	Whether results are audited or unaudited	Audited	Audited	Audited	Audited
D	Nature of report standalone or consolidated	Standalone	Standalone	Standalone	Standalone
1	**Income from Operations**				
	(a) Net Sales/Revenue from Operations	1,338.511	1,320.039	3,553.393	**4,697.813**
	(b) Other Income	7.213	6.315	16.233	45.035
	Total Income from Operations	**1,345.724**	**1,326.354**	**3,569.626**	**4,742.848**
				-	
2	**Expenses**				
	(a) Cost of Materials consumed	758.010	725.581	2,197.476	2,995.945
	(b) Purchase of stock-in-trade	49.679		49.679	
	(c) Employee benefits expenses	296.890	301.177	881.322	1,172.932
	(d) Finance Costs	31.541	26.661	86.990	111.575
	(e) Depreciation and amortisation expense	26.000	31.500	66.577	108.620
	(f) Other expenses	85.576	91.323	234.551	317.441
	Total Expenses	**1,247.695**	**1,176.242**	**3,516.596**	**4,706.512**
3	**Total profit / (Loss) before exceptional items and tax**	**98.029**	**150.112**	**53.030**	**36.336**
4	Exceptional Items			-	
5	**Total profit / (Loss) before tax**	98.029	150.112	53.030	36.336
7	**Tax Expenses**				
8	Current Tax		13.807		20.342
9	Deferred Tax		7.626		11.236
10	**Total Tax Expenses**	**-**	**21.433**	**-**	**31.578**
11	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement				
14	**Net Profit Loss for the period from continuing operations**	98.029	128.679	53.030	4.758
15	**Profit (loss) from discontinued operations before tax**			**-**	
16	**Tax expense of discontinued operations**			**-**	
17	**Net profit (loss) from discontinued operation after tax**			**-**	
19	**Share of profit (loss) of associates and joint ventures accounted for using equity method**			**-**	
21	**Total profit (loss) for period**	98.029	128.679	53.030	4.758
22	**Other comprehensive income net of taxes**			**-**	
23	**Total Comprehensive Income for the period**			**-**	
24	**Total profit or loss, attributable to**			**-**	
	Profit or loss, attributable to owners of parent	98.029	128.679	53.030	4.758
	Total profit or loss, attributable to non-controlling interests			**-**	

25	**Total Comprehensive income for the period attributable to**			-	
	Comprehensive income for the period attributable to owners of parent			-	
	Total comprehensive income for the period attributable to owners of parent noncontrolling interests			-	
26	**Details of equity share capital**			-	
	Paid-up equity share capital	3,422.720	3,422.720	3,422.720	3,422.720
	Face value of equity share capital	10.000	10.000	10.000	10.000
27	**Details of debt securities**				
	Paid-up debt capital				
	Face value of debt securities				
28	**Reserves excluding revaluation reserve**				
29	**Debenture redemption reserve**				
30	**Earnings per share**				
i	**Earnings per equity share for continuing operations**	0.286	0.376	0.155	0.014
	Basic earnings (loss) per share from continuing operations	0.286	0.376	0.155	0.014
	Diluted earnings (loss) per share from continuing operations				
ii	**Earnings per equity share for discontinued operations**				
	Basic earnings (loss) per share from discontinued operations				
	Diluted earnings (loss) per share from discontinued operations				
iii	**Earnings per equity share**				
	Basic earnings (loss) per share from continuing and discontinued operations	0.286	0.376	0.155	0.014
	Diluted earnings (loss) per share from continuing and discontinued operations	0.286	0.376	0.155	0.014
31	**Debt equity ratio**				
32	**Debt service coverage ratio**				
33	**Interest service coverage ratio**				
34	**Disclosure of notes on financial results**				

Notes:

1. The audited merged financial results for the Quarter ended June 30th,September 30th ,December 31st ,March 31st of 2018-19 and 2019-20 and for the Quarter ended 30th June of 2020-2021 being forwarded to the Bombay stock exchange and is also available in the website of the Company (www.indrayani.com)

2. The above financial results have been filed pursuant to the merger order by the Hon'ble National Company Law Tribunal Chennai dated 05.08.2020

3. The Company operates in single business segment. Hence no segment wise reporting figures are published.

4. There were no investor complaints pending at the beginning or at the end of the quarter. No complaints were received during the quarter

5. Previous period figures have been regrouped wherever necessary.

INDRAYANI BIOTECH LTD

Place: Chennai

Date: 22.06.2021

K SAYEE SUNDAR

MANAGING DIRECTOR

DIN: 01295584

INDRAYANI BIOTECH LIMITED

Regd. Office :SIDCO Electronics Complex, #32 33 Block: I 3rd Floor Thiru Vi Ka Industrial Estate SIDCO Industrial Estate Guindy Chennai Tamil Nadu 600032.

AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th June 2020

Rs. In Lakhs

Sr No	PARTICULARS	3 months ended 30/06/2020	3 months ended 31/03/2020	3 months ended 30/06/2019	Previous Year ended 31/03/2020
	PARTICULARS				
A	Date of start of reporting period	01-04-2020	01-01-2020	01-04-2019	01-04-2019
B	Date of end of reporting period	30-06-2020	31-03-2020	30-06-2019	31-03-2020
C	Whether results are audited or unaudited	Audited	Audited	Audited	Audited
D	Nature of report standalone or consolidated	Standalone	Standalone	Standalone	Standalone
1	**Income from Operations**				
	(a) Net Sales/Revenue from Operations	341.11	1,436.30	1,013.55	**4,989.69**
	(b) Other Income	7.09	3.47	2.98	19.70
	Total Income from Operations	**348.20**	**1,439.77**	**1,016.53**	**5,009.39**
				-	
2	**Expenses**			-	
	(a) Cost of Materials consumed	573.26	1,000.86	712.63	3,198.33
	(b) Purchase of stock-in-trade	-			49.68
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-		-	
	(d) Employee benefits expenses	239.08	253.48	307.94	1,134.80
	(e) Finance Costs	29.27	28.11	27.82	115.10
	(f) Depreciation and amortisation expense	21.25	34.87	19.27	101.44
	(g) Other expenses	119.35	94.71	79.70	329.26
	Total Expenses	**982.19**	**1,412.02**	**1,147.37**	**4,928.62**
3	**Total profit / (Loss) before exceptional items and tax**	**(633.99)**	**27.75**	**(130.84)**	**80.78**
4	Exceptional Items			-	
5	**Total profit / (Loss) before tax**	(633.99)	27.75	(130.84)	80.78
7	**Tax Expenses**				
8	Current Tax				
9	Deferred Tax				
10	**Total Tax Expenses**	-	-	-	-
11	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement				
14	**Net Profit Loss for the period from continuing operations**	(633.99)	27.75	(130.84)	80.78
15	**Profit (loss) from discontinued operations before tax**			-	
16	**Tax expense of discontinued operations**			-	
17	**Net profit (loss) from discontinued operation after tax**			-	
19	**Share of profit (loss) of associates and joint ventures accounted for using equity method**			-	
21	**Total profit (loss) for period**	(633.99)	27.75	(130.84)	80.78
22	**Other comprehensive income net of taxes**			-	
23	**Total Comprehensive Income for the period**			-	
24	**Total profit or loss, attributable to**			-	
	Profit or loss, attributable to owners of parent	(633.99)	27.75	(130.84)	80.78
	Total profit or loss, attributable to non-controlling interests			-	
25	**Total Comprehensive income for the period attributable to**			-	
	Comprehensive income for the period attributable to owners of parent			-	

	Total comprehensive income for the period attributable to owners of parent noncontrolling interests			-	
26	**Details of equity share capital**			-	
	Paid-up equity share capital	3,422.72	3,422.72	3,422.72	3,422.72
	Face value of equity share capital	10.00	10.00	10.00	10.00
27	**Details of debt securities**				
	Paid-up debt capital				
	Face value of debt securities				
28	**Reserves excluding revaluation reserve**				
29	**Debenture redemption reserve**				
30	**Earnings per share**				
i	**Earnings per equity share for continuing operations**	(1.85)	0.08	(0.38)	0.24
	Basic earnings (loss) per share from continuing operations	(1.85)	0.08	(0.38)	0.24
	Diluted earnings (loss) per share from continuing operations				
ii	**Earnings per equity share for discontinued operations**				
	Basic earnings (loss) per share from discontinued operations				
	Diluted earnings (loss) per share from discontinued operations				
iii	**Earnings per equity share**				
	Basic earnings (loss) per share from continuing and discontinued operations	(1.85)	0.08	(0.38)	0.24
	Diluted earnings (loss) per share from continuing and discontinued operations	(1.85)	0.08	(0.38)	0.24
31	**Debt equity ratio**				
32	**Debt service coverage ratio**				
33	**Interest service coverage ratio**				
34	**Disclosure of notes on financial results**				

Notes:

1. The audited merged financial results for the Quarter ended June 30th,September 30th ,December 31st ,March 31st of 2018-19 and 2019-20 and for the Quarter ended 30th June of 2020-2021 being forwarded to the Bombay stock exchange and is also available in the website of the Company (www.indrayani.com)

2. The above financial results have been filed pursuant to the merger order by the Hon'ble National Company Law Tribunal Chennai dated 05.08.2020

3. The Company operates in single business segment. Hence no segment wise reporting figures are published.

4. There were no investor complaints pending at the beginning or at the end of the quarter. No complaints were received during the quarter

5. Previous period figures have been regrouped wherever necessary.

INDRAYANI BIOTECH LTD

Place: Chennai

Date: 22.06.2021

K SAYEE SUNDAR

MANAGING DIRECTOR

DIN: 01295584